The Ministry of Health of Russia has registered an anticancer drug developed in Cuba for use in certain oncological treatments, an authorization that opens a new regulatory pathway for Cuban biotechnology in the Russian pharmaceutical market.
The product, commercially known as Nimolancim (Нимоланцим®), contains as its active ingredient nimotuzumab, a monoclonal antibody produced by the Molecular Immunology Center (CIM), based in Havana, as stated in the State Register of Medicines of Russia (GRLS).
The authorization was granted on October 6, 2026, valid until October 6, 2031, in accordance with the registration certificate ЛП-№(016793)-(РГ-RU) (official registration number of the medication in Russia).
The announcement was made public on October 15, when the Russian agency Interfax reported, citing the Ministry of Health of Russia, about the addition of the medication to the national pharmaceutical registry.
According to ministerial information released by Interfax, the product is intended for the treatment of adult patients with certain malignant tumors, including some of the esophagus, head and neck, as well as certain brain tumors.
The authorization pertains to specific oncological indications and does not mean that the medication can be used interchangeably for any type of cancer.
The Russian Ministry has presented the registry as an expansion of the targeted therapy options available for oncology practice in the country.
The nimotuzumab belongs to the group of monoclonal antibodies and acts on the epidermal growth factor receptor, commonly referred to by its English acronym EGFR.
This receptor is involved in processes related to cell growth and proliferation. Its activity may be altered in certain types of tumors, making it one of the targets used in targeted oncology treatments.
The Cuban medication is classified in the Russian registry as an EGFR inhibitor, within the pharmacotherapeutic group of antineoplastic agents.
It is not a vaccine against cancer, but a medication based on a monoclonal antibody that is administered by infusion.
The authorized presentation consists of a concentrate of 5 milligrams per milliliter (5 mg/ml) for preparing a solution intended for intravenous infusion.
The register includes 10-milliliter vials, packaged in sets of four units, and specifies that the product must be stored between 2 and 8 degrees Celsius, protected from light and not frozen.
The declared shelf life for the finished medicine is three years, under the specified storage conditions.
One of the most important aspects of the registry is the identification of the companies and institutions involved in its production.
The Russian company AO Lancet (АО «Ланцет») is listed as the holder of the registration certificate, identifying it as the entity responsible for the authorization of the medication in Russia.
However, the record clearly distinguishes between administrative ownership and the different stages of manufacturing.
The Center for Molecular Immunology of Havana is listed as the manufacturer of the pharmaceutical substance and the finished medication, in addition to participating in primary packaging, other conditioning phases, and quality control activities.
On its part, the Russian company AO Biokhimik, located in Saransk, Republic of Mordovia, is among the entities responsible for secondary and tertiary packaging, as well as quality control for product release.
The documentation thus reflects a production chain in which the Cuban institution retains fundamental responsibilities for manufacturing, while Russian companies assume specific regulatory and industrial roles.
Interfax reported precisely that distribution of responsibilities, stating that the medication is produced through international cooperation with the Cuban Center for Molecular Immunology.
The Russian Ministry of Health also identified Biokhimik as a participant in secondary conditioning and final quality control.
However, the record does not provide information about the quantities that will be produced or shipped to Russia, nor does it specify the price of the product or the economic conditions of the agreements between the involved entities.
It also does not allow for an estimate of how much money Cuba could generate from the eventual commercialization of the drug.
The health authorization is an important regulatory requirement, but on its own, it does not confirm that sales have begun, that the product is available in Russian hospitals, or that there are any executed supply contracts.
Similarly, the Russian registration does not imply automatic authorization to market the drug in other markets, such as the United States or the European Union, where independent regulatory procedures exist.
The nimotuzumab is part of the research and development journey of the Molecular Immunology Center, a Cuban institution specialized in biotechnological products and treatments based on monoclonal antibodies.
Its incorporation into the Russian registry occurs in the context of growing cooperation between the two countries in the pharmaceutical and biotechnology sectors.
In June, Cuba and Russia announced a memorandum of understanding to jointly develop vaccines against cancer, during the St. Petersburg International Economic Forum.
Russian Deputy Prime Minister Dmitry Chernishenko explained that the cooperation would include projects related to cancer treatments and recalled that Russia had previously supplied substances intended for the production of medicines in Cuba.
That memorandum addressed the joint development of therapeutic vaccines against cancer, a line of research distinct from nimotuzumab, which is a monoclonal antibody and already has a history of pharmaceutical development.
Related videos:
Filed under: